A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

659

Participants

Timeline

Start Date

January 23, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Herpes Zoster
Interventions
BIOLOGICAL

mRNA-1468

Sterile liquid dispersion for injection

BIOLOGICAL

Placebo

Sterile liquid for injection

BIOLOGICAL

Shingrix

Sterile suspension for injection

Trial Locations (20)

19107

DM Clinical Research - Philadelphia, Philadelphia

31904

Centricity Research, Columbus

32789

Florida Pulmonary Research Institute, LLC, Winter Park

33016

Floridian Clinical Research, Miami Lakes

33186

Clinical Trials of Florida, LLC, Miami

33805

Meridien Research, Lakeland

37421

WR-ClinSearch, LLC, Chattanooga

51106

Meridian Clinical Research - Dakota Dunes, Sioux City

60305

DM Clinical Research- River Forest, River Forest

60640

Great Lakes, Chicago

66219

Johnson County Clin-Trials (JCCT), Lenexa

70115

NOLA Research Works, New Orleans

77087

LinQ Research, LLC, Houston

77375

DM Clinical Research, Tomball

77702

Gadolin Research, Beaumont

78745

Tekton Research, Austin

80501

Tekton Research, Inc - Longmont Center, Longmont

90057

Velocity Clinical Research - Westlake, Los Angeles

97504

Velocity Clinical Research - Medford, Medford

00907

Research Works San Juan, San Juan

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY